Axel Åkerblom

SGLT2 inhibition reduces myocardial oxygen consumption

Søndergaard, Esben; Lauritzen, Esben S; Lauritsen, Katrine M; Åkerblom, Axel et al.

Ingår i Metabolism Open, 2022

• DOI för SGLT2 inhibition reduces myocardial oxygen consumption
• Ladda ner fulltext (pdf) av SGLT2 inhibition reduces myocardial oxygen consumption

Associations of Polymorphisms in the Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha Gene With Subsequent Coronary Heart Disease: An Individual-Level Meta-Analysis

Schillemans, Tessa; Tragante, Vinicius; Maitusong, Buamina; Gigante, Bruna et al.

Ingår i Frontiers in Physiology, 2022

• DOI för Associations of Polymorphisms in the Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha Gene With Subsequent Coronary Heart Disease: An Individual-Level Meta-Analysis
• Ladda ner fulltext (pdf) av Associations of Polymorphisms in the Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha Gene With Subsequent Coronary Heart Disease: An Individual-Level Meta-Analysis

Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study

Prescott, Eva; Angeras, Oskar; Erlinge, David; Grove, Erik L. et al.

Ingår i International Journal of Cardiology, s. 34-40, 2022

• DOI för Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study
• Ladda ner fulltext (pdf) av Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study

Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study

Oldgren, Jonas; Laurila, Sanna; Åkerblom, Axel; Latva-Rasku, Aino et al.

Ingår i Diabetes, obesity and metabolism, s. 1505-1517, 2021

• DOI för Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study

ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial

Ueland, Thor; Åkerblom, Axel; Ghukasyan, Tatevik; Michelsen, Annika E et al.

Ingår i Atherosclerosis, s. 35-41, 2020

• DOI för ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial

SGLT2 inhibition reduces myocardial oxygen consumption

Søndergaard, Esben; Lauritzen, Esben S; Lauritsen, Katrine M; Åkerblom, Axel et al.

Ingår i Metabolism Open, 2022

• DOI för SGLT2 inhibition reduces myocardial oxygen consumption
• Ladda ner fulltext (pdf) av SGLT2 inhibition reduces myocardial oxygen consumption

Associations of Polymorphisms in the Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha Gene With Subsequent Coronary Heart Disease: An Individual-Level Meta-Analysis

Schillemans, Tessa; Tragante, Vinicius; Maitusong, Buamina; Gigante, Bruna et al.

Ingår i Frontiers in Physiology, 2022

• DOI för Associations of Polymorphisms in the Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha Gene With Subsequent Coronary Heart Disease: An Individual-Level Meta-Analysis
• Ladda ner fulltext (pdf) av Associations of Polymorphisms in the Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha Gene With Subsequent Coronary Heart Disease: An Individual-Level Meta-Analysis

Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study

Prescott, Eva; Angeras, Oskar; Erlinge, David; Grove, Erik L. et al.

Ingår i International Journal of Cardiology, s. 34-40, 2022

• DOI för Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study
• Ladda ner fulltext (pdf) av Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study

Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study

Oldgren, Jonas; Laurila, Sanna; Åkerblom, Axel; Latva-Rasku, Aino et al.

Ingår i Diabetes, obesity and metabolism, s. 1505-1517, 2021

• DOI för Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study

ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial

Ueland, Thor; Åkerblom, Axel; Ghukasyan, Tatevik; Michelsen, Annika E et al.

Ingår i Atherosclerosis, s. 35-41, 2020

• DOI för ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial

Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction

Prescott, Eva; Pernow, John; Saraste, Antti; Åkerblom, Axel et al.

Ingår i Contemporary Clinical Trials Communications, 2020

• DOI för Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction
• Ladda ner fulltext (pdf) av Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction

Association of Factor V Leiden With Subsequent Atherothrombotic Events A GENIUS-CHD Study of Individual Participant Data

Mahmoodi, Bakhtawar K.; Tragante, Vinicius; Kleber, Marcus E.; Holmes, Michael V. et al.

Ingår i Circulation, s. 546-555, 2020

• DOI för Association of Factor V Leiden With Subsequent Atherothrombotic Events A GENIUS-CHD Study of Individual Participant Data

Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics.

Morales-Rosado, Joel A; Goel, Kashish; Zhang, Lingxin; Åkerblom, Axel et al.

Ingår i Cardiovascular Drugs and Therapy, s. 549-559, 2020

• DOI för Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics.

Legumain in Acute Coronary Syndromes: A Substudy of the PLATO (Platelet Inhibition and Patient Outcomes) Trial

Gregersen, Ida; Michelsen, Annika E.; Lunde, Ngoc Nguyen; Åkerblom, Axel et al.

Ingår i Journal of the American Heart Association, 2020

• DOI för Legumain in Acute Coronary Syndromes: A Substudy of the PLATO (Platelet Inhibition and Patient Outcomes) Trial

Pentraxin-3 vs C-reactive protein and other prognostic biomarkers in acute coronary syndrome: A substudy of the Platelet Inhibition and Patients Outcomes (PLATO) trial

Kontny, Frederic; Andersen, Thomas; Ueland, Thor; Åkerblom, Axel et al.

Ingår i European Heart Journal, s. 313-322, 2020

• DOI för Pentraxin-3 vs C-reactive protein and other prognostic biomarkers in acute coronary syndrome: A substudy of the Platelet Inhibition and Patients Outcomes (PLATO) trial

Treatments and Mortality Trends in Cases With and Without Dialysis Who Have an Acute Myocardial Infarction: An 18-Year Nationwide Experience

Szummer, Karolina; Lindhagen, Lars; Evans, Marie; Spaak, Jonas et al.

Ingår i Circulation. Cardiovascular Quality and Outcomes, 2019

• DOI för Treatments and Mortality Trends in Cases With and Without Dialysis Who Have an Acute Myocardial Infarction: An 18-Year Nationwide Experience

Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATelet inhibition and patient Outcomes (PLATO) trial

Åkerblom, Axel; Wojdyla, Daniel; Steg, Philippe Gabriel; Wallentin, Lars et al.

Ingår i Journal of Thrombosis and Thrombolysis, s. 563-569, 2019

• DOI för Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATelet inhibition and patient Outcomes (PLATO) trial
• Ladda ner fulltext (pdf) av Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATelet inhibition and patient Outcomes (PLATO) trial

Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events: A GENIUS-CHD Study of Individual Participant Data

Patel, Riyaz S.; Schmidt, Amand F.; Tragante, Vinicius; McCubrey, Raymond O. et al.

Ingår i Circulation, 2019

• DOI för Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events: A GENIUS-CHD Study of Individual Participant Data
• Ladda ner fulltext (pdf) av Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events: A GENIUS-CHD Study of Individual Participant Data

Subsequent Event Risk in Individuals With Established Coronary Heart Disease: Design and Rationale of the GENIUS-CHD Consortium

Patel, Riyaz S.; Tragante, Vinicius; Schmidt, Amand F.; McCubrey, Raymond O. et al.

Ingår i Circulation, 2019

• DOI för Subsequent Event Risk in Individuals With Established Coronary Heart Disease: Design and Rationale of the GENIUS-CHD Consortium
• Ladda ner fulltext (pdf) av Subsequent Event Risk in Individuals With Established Coronary Heart Disease: Design and Rationale of the GENIUS-CHD Consortium

C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary Syndromes

Andersen, Thomas; Ueland, Thor; Ghukasyan Lakic, Tatevik; Åkerblom, Axel et al.

Ingår i Arteriosclerosis, Thrombosis and Vascular Biology, s. 2402-2410, 2019

• DOI för C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary Syndromes

Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention

Kessler, Thorsten; Wolf, Bernhard; Eriksson, Niclas; Kofink, Daniel et al.

Ingår i Cardiovascular Research, s. 1512-1518, 2019

• DOI för Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention

Ticagrelor in patients with heart failure after acute coronary syndromes - Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial

Åkerblom, Axel; Wojdyla, Daniel M.; Wallentin, Lars; James, Stefan et al.

Ingår i American Heart Journal, s. 57-65, 2019

• DOI för Ticagrelor in patients with heart failure after acute coronary syndromes - Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial

Admission Levels of DKK1 (Dickkopf-1) Are Associated With Future Cardiovascular Death in Patients With Acute Coronary Syndromes

Ueland, Thor; Åkerblom, Axel; Ghukasyan, Tatevik; Michelsen, Annika E et al.

Ingår i Arteriosclerosis, Thrombosis and Vascular Biology, s. 294-302, 2019

• DOI för Admission Levels of DKK1 (Dickkopf-1) Are Associated With Future Cardiovascular Death in Patients With Acute Coronary Syndromes

Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study

Parker, William A E; Eriksson, Niclas; Becker, Richard C; Voora, Deepak et al.

Ingår i Platelets, s. 579-588, 2019

• DOI för Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study

Interleukin-18 in patients with acute coronary syndromes.

Åkerblom, Axel; James, Stefan K.; Lakic, Tatevik G; Becker, Richard C et al.

Ingår i Clinical Cardiology, s. 1202-1209, 2019

• DOI för Interleukin-18 in patients with acute coronary syndromes.

Effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency, and myocardial contractile work in type 2 diabetes patients - a description of the DAPACARD study

Åkerblom, Axel; Oldgren, Jonas; Latva-Rasku, Aino; Johansson, Lars et al.

Ingår i Upsala Journal of Medical Sciences, s. 59-64, 2019

• DOI för Effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency, and myocardial contractile work in type 2 diabetes patients - a description of the DAPACARD study
• Ladda ner fulltext (pdf) av Effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency, and myocardial contractile work in type 2 diabetes patients - a description of the DAPACARD study

Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial

Ueland, Thor; Åkerblom, Axel; Ghukasyan, Tatevik; Michelsen, Annika E. et al.

Ingår i Journal of the American Heart Association, 2018

• DOI för Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial
• Ladda ner fulltext (pdf) av Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial

Novel Cyp2C19 Genetic Variants associated with Stent Thrombosis: a Next Generation Sequencing Study

Goel, Kashish; Baheti, Saurabh; Åkerblom, Axel; Eriksson, Niclas et al.

Ingår i Journal of the American College of Cardiology, s. 1205-1205, 2018

• DOI för Novel Cyp2C19 Genetic Variants associated with Stent Thrombosis: a Next Generation Sequencing Study

Seasonal variations of urate in a Swedish adult population

Åkerblom, Axel; Helmersson, Johanna; Weitoft, Tomas; Larsson, Anders

Ingår i Clinical Rheumatology, s. 1595-1598, 2017

• DOI för Seasonal variations of urate in a Swedish adult population
• Ladda ner fulltext (pdf) av Seasonal variations of urate in a Swedish adult population

An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome

Pagidipati, Neha J.; Hess, Connie N.; Clare, Robert M.; Akerblom, Axel et al.

Ingår i American Heart Journal, s. 53-61, 2017

• DOI för An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome

Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study

Zewinger, Stephen; Kleber, Marcus E.; Tragante, Vinicius; McCubrey, Raymond O. et al.

Ingår i The Lancet Diabetes and Endocrinology, s. 534-543, 2017

• DOI för Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study

Successful reperfusion is associated with lower levels of markers of myocardial damage and dysfunction in ST-elevation but not in non-ST-elevation myocardial infarction: insights from the PLATO trial

Varenhorst, Christoph; Åkerblom, Axel; Renlund, Henrik; Kunadian, V. et al.

Ingår i EUROPEAN HEART JOURNAL, s. 1282-1283, 2016

Serum Uric Acid Is Associated With Cardiovascular Outcomes In Patients With Acute Coronary Syndromes: Results From The Platelet Inhibition And Patient Outcomes (Plato) Trial

Åkerblom, Axel; James, Stefan; Bertilsson, Maria; Himmelmann, Anders et al.

Ingår i Journal of the American College of Cardiology, s. 556-556, 2016

Outcome after percutaneous coronary intervention for different indications: long-term results from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)

Fokkema, Marieke L.; James, Stefan K.; Albertsson, Per; Aasa, Mikael et al.

Ingår i EuroIntervention, s. 303-311, 2016

• DOI för Outcome after percutaneous coronary intervention for different indications: long-term results from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)

Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial

Åkerblom, Axel; Clare, Robert M.; Lokhnygina, Yuliya; Wallentin, Lars et al.

Ingår i American Heart Journal, s. 1-8, 2016

• DOI för Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial

Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction

Evans, Marie; Carrero, Juan-Jesus; Szummer, Karolina; Åkerblom, Axel et al.

Ingår i Journal of the American College of Cardiology, s. 1687-1697, 2016

• DOI för Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction

Comparison between cystatin C and creatinine estimated GFR in cardiology patients

Åkerblom, Axel; Helmersson-Karlqvist, Johanna; Flodin, Mats; Larsson, Anders

Ingår i Cardiorenal medicine, s. 289-296, 2015

• DOI för Comparison between cystatin C and creatinine estimated GFR in cardiology patients

Effect of genetic variations on ticagrelor plasma levels and clinical outcomes

Varenhorst, Christoph; Eriksson, Niclas; Johansson, Åsa; Barratt, Bryan J. et al.

Ingår i European Heart Journal, s. 1901-1912, 2015

• DOI för Effect of genetic variations on ticagrelor plasma levels and clinical outcomes

Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATelet Inhibition and Patient Outcomes (PLATO) Study

Åkerblom, Axel; Eriksson, Niclas; Wallentin, Lars; Siegbahn, Agneta et al.

Ingår i American Heart Journal, s. 96-102, 2014

• DOI för Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATelet Inhibition and Patient Outcomes (PLATO) Study

Efficacy and safety of ticagrelor in patients with acute coronary syndrome and heart failure: insights from the platelet inhibition and patient outcomes (PLATO) trial

Brito, F. S. B. De Souza; Åkerblom, Axel A.; Wojdyla, D. W.; Steg, P. G. S. et al.

Ingår i European Heart Journal, s. 202-203, 2014

Platelet RNA as a novel biomarker for the response to antiplatelet therapy

Voora, Deepak; Ginsburg, GS; Åkerblom, Axel

Ingår i Future Cardiology, s. 9-12, 2014

• DOI för Platelet RNA as a novel biomarker for the response to antiplatelet therapy

Cystatin C- and Creatinine-based Estimates of Renal Function and Their Value for Risk Prediction in Patients with Acute Coronary Syndrome: Results from the PLATelet Inhibition and Patient Outcomes (PLATO) Study

Åkerblom, Axel; Wallentin, Lars; Larsson, Anders; Siegbahn, Agneta et al.

Ingår i Clinical Chemistry, s. 1369-1375, 2013

• DOI för Cystatin C- and Creatinine-based Estimates of Renal Function and Their Value for Risk Prediction in Patients with Acute Coronary Syndrome: Results from the PLATelet Inhibition and Patient Outcomes (PLATO) Study

Are There Any Causal Relations Between Growth Differentiation Factor 15 and Outcomes in Patients With Acute Coronary Syndrome?: - A Report From the Plato Gwas Study

Hagström, Emil; Eriksson, Niclas; Johansson, Åsa; Bertilsson, Maria et al.

Ingår i Circulation, 2013

Evaluation of the Effect of Interleukin 18 Associated Genetic Polymorphisms on Risk of Cardiovascular Events in Patients With Acute Coronary Syndrome

Siegbahn, Agneta; Johansson, Åsa; Eriksson, Niclas; Hagström, Emil et al.

Ingår i Circulation, 2013

Genetic Polymorphism and Relationship to Cystatin C Concentrations and Outcome - Results From the Platelet Inhibition and Patient Outcomes Study

Åkerblom, Axel; Wallentin, Lars; Siegbahn, Agneta; Becker, Richard C. et al.

Ingår i Circulation, 2013

Population Trends in Percutaneous Coronary Intervention: 20 Year Results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry)

Fokkema, Marieke L; James, Stefan K; Albertsson, Per; Akerblom, Axel et al.

Ingår i Journal of the American College of Cardiology, s. 1222-1230, 2013

• DOI för Population Trends in Percutaneous Coronary Intervention: 20 Year Results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry)

Cystatin C and Estimated Glomerular Filtration Rate as Predictors for Adverse Outcome in Patients with ST-Elevation and Non-ST-Elevation Acute Coronary Syndromes: Results from the Platelet Inhibition and Patient Outcomes Study

Åkerblom, Axel; Wallentin, Lars; Siegbahn, Agneta; Becker, Richard C et al.

Ingår i Clinical Chemistry, s. 190-199, 2012

• DOI för Cystatin C and Estimated Glomerular Filtration Rate as Predictors for Adverse Outcome in Patients with ST-Elevation and Non-ST-Elevation Acute Coronary Syndromes: Results from the Platelet Inhibition and Patient Outcomes Study

Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients: Results from the PLATelet inhibition and patient Outcomes (PLATO) study

Åkerblom, Axel; Wallentin, Lars; Siegbahn, Agneta; Becker, R. C. et al.

Ingår i American Heart Journal, s. 728-734, 2012

• DOI för Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients: Results from the PLATelet inhibition and patient Outcomes (PLATO) study

Serial cystatin C measurements and changes in glomerular filtration rate as predictors for death or myocardial infarction in ACS patients

Åkerblom, Axel; Wallentin, Lars; Siegbahn, Agneta; Becker, R. C. et al.

Ingår i European Heart Journal, s. 135-135, 2012

• DOI för Serial cystatin C measurements and changes in glomerular filtration rate as predictors for death or myocardial infarction in ACS patients

Eptifibatide Is Noninferior to Abciximab in Primary Percutaneous Coronary Intervention Results From the SCAAR (Swedish Coronary Angiography and Angioplasty Registry)

Åkerblom, Axel; James, Stefan K.; Koutouzis, Michail; Lagerqvist, Bo et al.

Ingår i Journal of the American College of Cardiology, s. 470-475, 2010

• DOI för Eptifibatide Is Noninferior to Abciximab in Primary Percutaneous Coronary Intervention Results From the SCAAR (Swedish Coronary Angiography and Angioplasty Registry)

Long-Term Results Following Switch From Abciximab to Eptifibatide During Percutaneous Coronary Intervention

Koutouzis, Michael; Lagerqvist, Bo; Oldgren, Jonas; Åkerblom, Axel et al.

Ingår i Clinical Cardiology, s. 686-692, 2010

• DOI för Long-Term Results Following Switch From Abciximab to Eptifibatide During Percutaneous Coronary Intervention

Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial

James, Stefan; Åkerblom, Axel; Cannon, Christopher P.; Emanuelsson, Håkan et al.

Ingår i American Heart Journal, s. 599-605, 2009

• DOI för Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial

Biomarkers of Renal Function in Acute Coronary Syndromes

Åkerblom, Axel

2013

• Ladda ner fulltext (pdf) av Biomarkers of Renal Function in Acute Coronary Syndromes

Does a clinical history of gout influence the relationship of serum uric acid levels and cardiovascular outcomes among patients with acute coronary syndromes?

Pagidipati, N.; Hess, C. N.; Clare, R. M.; Åkerblom, Axel et al.

s. 458-458, 2016